96 related articles for article (PubMed ID: 10941537)
1. Effect of cisplatin-based chemotherapy on emergence of cisplatin resistance, and its correlation with intracellular glutathione levels and accumulation of p53 protein in human ovarian cancer.
Juvekar AS; Adwankar MK; Tongaonkar HB
Cancer Biother Radiopharm; 2000 Jun; 15(3):295-300. PubMed ID: 10941537
[TBL] [Abstract][Full Text] [Related]
2. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
3. Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer.
Lewandowicz GM; Britt P; Elgie AW; Williamson CJ; Coley HM; Hall AG; Sargent JM
Gynecol Oncol; 2002 May; 85(2):298-304. PubMed ID: 11972391
[TBL] [Abstract][Full Text] [Related]
4. Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer.
Kigawa J; Minagawa Y; Kanamori Y; Itamochi H; Cheng X; Okada M; Oishi T; Terakawa N
Cancer; 1998 Feb; 82(4):697-702. PubMed ID: 9477102
[TBL] [Abstract][Full Text] [Related]
5. Cellular glutathione level does not predict ovarian cancer cells' resistance after initial or repeated exposure to cisplatin.
Nikounezhad N; Nakhjavani M; Shirazi FH
J Exp Ther Oncol; 2017 May; 12(1):1-7. PubMed ID: 28472558
[TBL] [Abstract][Full Text] [Related]
6. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
7. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.
Metzinger DS; Taylor DD; Gercel-Taylor C
Cancer Lett; 2006 May; 236(2):302-8. PubMed ID: 15990222
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
[TBL] [Abstract][Full Text] [Related]
9. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas.
Mayr D; Pannekamp U; Baretton GB; Gropp M; Meier W; Flens MJ; Scheper R; Diebold J
Pathol Res Pract; 2000; 196(7):469-75. PubMed ID: 10926324
[TBL] [Abstract][Full Text] [Related]
11. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
12. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
13. Combining disulfiram and poly(l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance.
Song W; Tang Z; Shen N; Yu H; Jia Y; Zhang D; Jiang J; He C; Tian H; Chen X
J Control Release; 2016 Jun; 231():94-102. PubMed ID: 26928530
[TBL] [Abstract][Full Text] [Related]
14. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation.
Gibalová L; Sereš M; Rusnák A; Ditte P; Labudová M; Uhrík B; Pastorek J; Sedlák J; Breier A; Sulová Z
Toxicol In Vitro; 2012 Apr; 26(3):435-44. PubMed ID: 22269388
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
18. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells.
Abedini MR; Muller EJ; Brun J; Bergeron R; Gray DA; Tsang BK
Cancer Res; 2008 Jun; 68(12):4511-7. PubMed ID: 18559494
[TBL] [Abstract][Full Text] [Related]
20. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
Mohell N; Alfredsson J; Fransson Å; Uustalu M; Byström S; Gullbo J; Hallberg A; Bykov VJ; Björklund U; Wiman KG
Cell Death Dis; 2015 Jun; 6(6):e1794. PubMed ID: 26086967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]